John L Lamattina insider trades

Open-market stock purchases and sales by John L Lamattina, Director at Ligand Pharmaceuticals Inc, from SEC Form 4 filings since May 21, 2010.

Track record: 100% of 2 scored buys are up 5% or more since purchase, averaging +29%.

Recent trades

DateStockTradeValue
Jun 10, 2026LGND Ligand Pharmaceuticals IncSold$63.5K
Jun 10, 2026LGND Ligand Pharmaceuticals IncSold$57.6K
Jun 10, 2026LGND Ligand Pharmaceuticals IncSold$174K
Jun 10, 2026LGND Ligand Pharmaceuticals IncSold$857K
Jun 5, 2026LGND Ligand Pharmaceuticals IncBought (not open market)—
Jun 5, 2026LGND Ligand Pharmaceuticals IncBought (not open market)—
Mar 6, 2026LGND Ligand Pharmaceuticals IncSold$434K
Mar 6, 2026LGND Ligand Pharmaceuticals IncBought (not open market)—
Nov 7, 2025LGND Ligand Pharmaceuticals IncSold$441K
Nov 7, 2025LGND Ligand Pharmaceuticals IncSold$418K
Nov 7, 2025LGND Ligand Pharmaceuticals IncBought (not open market)—
Nov 7, 2025LGND Ligand Pharmaceuticals IncBought (not open market)—

Companies traded

  • LGND Ligand Pharmaceuticals Inc: 5 buys, 14 sales, last Jun 10, 2026
  • IMNM Immunome Inc: 2 buys, last Jun 8, 2023
  • ZFGN Zafgen, Inc: other filings, last Jun 26, 2019
  • HGSI Human Genome Sciences Inc: other filings, last Jul 30, 2012

Get free alerts when John L Lamattina files a new trade →